Viatris Inc - Company Profile
Powered by 
All the data and insights you need on Viatris Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Viatris Inc Strategy Report
- Understand Viatris Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Viatris Inc (Viatris) is a healthcare company, which develops, licenses, manufactures, markets and distributes generics and branded medicines, and consumer healthcare products. It offers pharmaceuticals in multiple forms for various disease conditions related to respiratory, cardiovascular, central nervous system (CNS) system and allergy, skin disease, and cancer. It also offers anti- retrovirals, anaphylaxis products, and active pharmaceutical ingredients (APIs). The company sells its products to retail pharmacy chains, wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. The company markets its products in various countries. Viatris is headquartered in Canonsburg, Pennsylvania, the US.
Headquarters
United States of America
Address
1000 Mylan Boulevard, Canonsburg, Pennsylvania, 15317
Website
www.viatris.com/en
Telephone
1 724 5141800
No of Employees
38,000
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
VTRS (NASD)
Revenue (2022)
$15.4B
-5.1%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-97.4%
(2022 vs 2021)
Market Cap*
$13.5B
Net Profit Margin (2022)
XYZ
-97.3%
(2022 vs 2021)
* As of and is in US$
Viatris Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| - | - |
| Generic Products | Balneol |
| Prescription Drug | Contac |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Divestiture | In March, the company sold its women's healthcare business to Insud Pharma. |
| 2024 | Contracts/Agreements | In February, the company entered into an agreement with Idorsia to secure global development and commercialization rights to two Phase 3 assets and the potential to add additional innovative assets. |
| 2023 | Contracts/Agreements | In November, the company entered into partnership with Comfort Cases to support children in the foster care system. |
Competitor Comparison
| Key Parameters | Viatris Inc | Merck & Co Inc | GSK plc | Teva Pharmaceutical Industries Ltd | Sandoz Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United Kingdom | Israel | United States of America |
| City | Canonsburg | Kenilworth | Brentford | Tel Aviv | Princeton |
| State/Province | Pennsylvania | New Jersey | England | Tel Aviv | New Jersey |
| No. of Employees | 38,000 | 72,000 | 70,212 | 35,001 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Robert J. Coury | Chairman | Executive Board | 2020 | - |
| Scott A. Smith | Chief Executive Officer; Director | Executive Board | 2023 | - |
| Corinne Le Goff | Chief Commercial Officer; Director | Executive Board | 2024 | - |
| Paul Campbell | Chief Accounting Officer; Controller | Senior Management | 2020 | - |
| Anthony Mauro | President - North America | Senior Management | 2020 | 49 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward